Peripheral blood stem cell collection in allogeneic donors: impact of venous access

Hölig, Kristina; Blechschmidt, Matthias; Kramer, Michael; Zimmer, Kristin; Kroschinsky, Frank; Poppe-Thiede, Kirsten; Bornhäuser, Martin; Ehninger, Gerhard

doi:10.1111/j.1537-2995.2012.03651.x

Cited by 20 publications

(16 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 98 Pain at the site of puncture occurs more frequently in donors with a central (58%) than peripheral vein access (38%). 99 The occurrence of acute side effects in large series of BM and PB HSPC harvests in donors has been compared, which showed that peak levels of pain and toxicities were comparable in both harvesting methods. 100 …”

Section: Pb Hspc Harvesting By Apheresismentioning

confidence: 99%

Hematopoietic stem and progenitor cell harvesting: technical advances and clinical utility

Héquet¹

2015

JBM

View full text Add to dashboard Cite

Hematopoietic stem and progenitor cell (HSPC) transplantations require prior harvesting of allogeneic or autologous HSPCs. HSPCs are usually present in bone marrow (BM) during the entire life, in cord blood (CB) at birth, or in peripheral blood (PB) under particular circumstances. HSPCs were first harvested in BM and later in CB and PB, as studies showed interesting features of such grafts. All harvesting methods were in use throughout the years, except BM harvesting for HSPC autologous transplantation, which was replaced by PB harvesting. BM, CB, and PB harvesting methods have been developed, and materials and devices technically improved to increase the number of HSPCs harvested. In parallel, knowing the features of the donors or patients associated with successful numbers of HSPCs allows the adaptation of appropriate harvesting methods. Moreover, it is important to ensure the safety of donors or patients while harvesting. This review describes the methods used for harvesting based on recent studies or developments around these methods, and more particularly, the means developed to increase the numbers of HSPCs harvested in each method. It also explains briefly the influence of technical improvements in HSPC harvesting on potential changes in HSPC graft composition.

show abstract

Section: Pb Hspc Harvesting By Apheresismentioning

confidence: 99%

Hematopoietic stem and progenitor cell harvesting: technical advances and clinical utility

Héquet¹

2015

JBM

View full text Add to dashboard Cite

show abstract

“…However, the jugular and subclavian veins have advantages in terms of bacterial contamination, but their disadvantage is the risk of pneumothorax or hemothorax and air embolism due to improper catheter manipulation. The femoral vein is often discouraged due to the high incidence of bacterial infection and thrombosis, in addition to the need of the patient to remain in bed during the time in which the use of the catheter is required 20 - 21 .…”

Section: Discussionmentioning

confidence: 99%

Complications of central venous catheter in patients transplanted with hematopoietic stem cells in a specialized service

Barretta¹,

Beccária

Cesarino

et al. 2016

Rev. Latino-Am. Enfermagem

View full text Add to dashboard Cite

Objective: to identify the model, average length of stay on site and complications of central venous catheter in patients undergoing transplant of hematopoietic stem cells and verify the corresponding relationship between the variables: age, gender, medical diagnosis, type of transplant, implanted catheter and insertion site. Method: a retrospective and quantitative study with a sample of 188 patients transplanted records between 2007 and 2011. Results: the majority of patients used Hickman catheter with an average length of stay on site of 47.6 days. The complication fever/bacteremia was significant in young males with non-Hodgkin's lymphoma undergoing autologous transplant, which remained with the device for a long period in the subclavian vein. Conclusion: nurses should plan with their team the minimum waiting time, recommended between the catheter insertion and start of the conditioning regimen, as well as not to extend the length of time that catheter should be on site and undertake their continuing education, focusing on the prevention of complications.

show abstract

“…A review of the literature on the topic of vascular access for leukapheresis shows an ongoing discussion about whether to use 1) peripheral cannulae, 2) central lines, or 3) a combination of both to perform apheresis with optimal efficacy. [11][12][13][14][15][16][17] Specifically, for options 2 and 3, the question of using permanent or temporary central venous catheters is still under debate. 11,14,18,19 While most of these studies were performed in adult patients, there are limited data specifically addressing the topic of venous access in pediatric oncology patients.…”

Section: From the 1 Department For Children And Adolescents Divisionmentioning

confidence: 99%

“…After the mononuclear cell (MNC) fraction containing the CD34+ PBSCs is extracted, the blood is returned to the patient via the second venous access (inlet). A review of the literature on the topic of vascular access for leukapheresis shows an ongoing discussion about whether to use 1) peripheral cannulae, 2) central lines, or 3) a combination of both to perform apheresis with optimal efficacy . Specifically, for options 2 and 3, the question of using permanent or temporary central venous catheters is still under debate .…”

mentioning

confidence: 99%

Mobilized peripheral blood stem cell apheresis via Hickman catheter in pediatric patients

et al. 2019

View full text Add to dashboard Cite

BACKGROUND Autologous stem cell transplantation remains an integral treatment tool for certain childhood malignancies. In children, a central venous catheter is typically necessary to provide adequate flow rates for preparative apheresis. In this study, the feasibility and efficiency of collecting CD34+ cells via an indwelling Hickman catheter, preimplanted for chemotherapy, instead of placing an additional temporary central venous catheter was evaluated. STUDY DESIGN AND METHODS Forty‐eight pediatric leukaphereses for autologous hematopoietic stem cell transplantation using Spectra Optia MNC, Version 3.0 were reviewed. We compared preimplanted Hickman catheters with a temporary Shaldon catheter, inserted for apheresis. Apheresis was considered successful if a dose of 2 × 106 CD34+ peripheral blood stem cells/kg BW was achieved. RESULTS In 43 (89.6%) of the 48 patients, a Hickman catheter was used for leukapheresis. Only 5 patients (10.4%) received a temporary Shaldon catheter. In both groups, apheresis was performed without apparent adverse reactions. The dose of collected CD34+ peripheral blood stem cells was 12.7 × 106 (range, 2.3–70.7 × 106) cells/kg BW in the Hickman group and 16.2 × 106 (range, 3.8–48.4 × 106) cells/kg BW in the Shaldon group, showing no statistically significant difference (p = 0.58). In both groups, the primary endpoint of a minimal CD34+ cell concentration of 2 × 106 cells/kg BW was achieved at a maximum of two leukapheresis sessions. Apheresis efficacy was further confirmed by the collection efficiency of 40.2% in the Hickman group and 27.8% in the Shaldon group (p = 0.32). CONCLUSION These data indicate the reliable feasibility and efficacy of mobilized apheresis via an indwelling Hickman catheter. In light of this, the routine insertion of a dialysis catheter for the purpose of leukapheresis should be critically reconsidered.

show abstract

Peripheral blood stem cell collection in allogeneic donors: impact of venous access

Abstract: Central femoral lines proved to be safe and tolerable in healthy allogeneic donors but peripheral venous access should be preferred, whenever possible.

Cited by 20 publications

References 16 publications

Hematopoietic stem and progenitor cell harvesting: technical advances and clinical utility

Hematopoietic stem and progenitor cell harvesting: technical advances and clinical utility

Complications of central venous catheter in patients transplanted with hematopoietic stem cells in a specialized service

Mobilized peripheral blood stem cell apheresis via Hickman catheter in pediatric patients

Contact Info

Product

Resources

About